Free Trial

Salarius Pharmaceuticals (SLRX) Competitors

Salarius Pharmaceuticals logo
$0.78 -0.22 (-21.69%)
Closing price 04:00 PM Eastern
Extended Trading
$0.76 -0.03 (-3.55%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SLRX vs. ENSC, QLGN, SPRB, VIVS, MTNB, ORGS, GLTO, ADIL, GRI, and REVB

Should you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Ensysce Biosciences (ENSC), Qualigen Therapeutics (QLGN), Spruce Biosciences (SPRB), VivoSim Labs (VIVS), Matinas Biopharma (MTNB), Orgenesis (ORGS), Galecto (GLTO), Adial Pharmaceuticals (ADIL), GRI Bio (GRI), and Revelation Biosciences (REVB). These companies are all part of the "pharmaceutical products" industry.

Salarius Pharmaceuticals vs. Its Competitors

Salarius Pharmaceuticals (NASDAQ:SLRX) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, Salarius Pharmaceuticals had 11 more articles in the media than Ensysce Biosciences. MarketBeat recorded 12 mentions for Salarius Pharmaceuticals and 1 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 1.89 beat Salarius Pharmaceuticals' score of 0.19 indicating that Ensysce Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Salarius Pharmaceuticals Neutral
Ensysce Biosciences Very Positive

11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 1.2% of Salarius Pharmaceuticals shares are owned by insiders. Comparatively, 7.9% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Salarius Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Salarius Pharmaceuticals has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -109.49%. Ensysce Biosciences' return on equity of -192.54% beat Salarius Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Salarius PharmaceuticalsN/A -324.13% -174.40%
Ensysce Biosciences -109.49%-192.54%-121.77%

Ensysce Biosciences is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Salarius PharmaceuticalsN/AN/A-$5.58M-$4.82-0.16
Ensysce BiosciencesN/AN/A-$7.99M-$6.54-0.32

Summary

Salarius Pharmaceuticals beats Ensysce Biosciences on 6 of the 11 factors compared between the two stocks.

Get Salarius Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLRX vs. The Competition

MetricSalarius PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.67M$2.46B$5.59B$9.53B
Dividend YieldN/A1.77%4.71%4.03%
P/E Ratio-0.169.4927.9619.93
Price / SalesN/A427.91389.5465.88
Price / CashN/A165.5736.3258.75
Price / Book0.824.968.375.77
Net Income-$5.58M$31.62M$3.25B$259.10M
7 Day Performance11.83%-3.27%-2.50%-3.41%
1 Month Performance-12.62%9.78%7.98%8.53%
1 Year Performance-76.28%-5.75%34.65%15.75%

Salarius Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLRX
Salarius Pharmaceuticals
0.3001 of 5 stars
$0.78
-21.7%
N/A-73.2%$1.67MN/A-0.1620Trending News
Gap Down
High Trading Volume
ENSC
Ensysce Biosciences
0.9559 of 5 stars
$2.17
+1.9%
N/A-67.4%$5.05M$5.21M-0.3310
QLGN
Qualigen Therapeutics
N/A$3.07
+2.0%
N/A-78.0%$4.92M$4.98M0.0050News Coverage
Gap Down
SPRB
Spruce Biosciences
2.1263 of 5 stars
$0.12
+5.7%
$1.75
+1,404.7%
-77.6%$4.91M$4.91M-0.1220Stock Split
VIVS
VivoSim Labs
N/A$1.98
+4.8%
N/AN/A$4.91M$140K-0.1920
MTNB
Matinas Biopharma
N/A$0.95
-0.6%
N/AN/A$4.85MN/A-0.2030
ORGS
Orgenesis
1.7241 of 5 stars
$1.01
-2.9%
N/AN/A$4.85M$662K0.00150Upcoming Earnings
Gap Up
GLTO
Galecto
3.6995 of 5 stars
$3.60
+0.3%
$10.00
+177.8%
-74.4%$4.74MN/A-0.2340
ADIL
Adial Pharmaceuticals
2.7131 of 5 stars
$0.51
+12.4%
$8.00
+1,477.9%
-42.8%$4.71MN/A-0.3520
GRI
GRI Bio
2.9121 of 5 stars
$1.99
+9.3%
$22.00
+1,005.5%
-85.9%$4.54MN/A-0.171Gap Up
REVB
Revelation Biosciences
1.8712 of 5 stars
$3.06
+3.7%
N/A-96.7%$4.53MN/A-0.0110Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:SLRX) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners